How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?

被引:88
作者
Svensson, M
Gustafsson, F
Galatius, S
Hildebrandt, PR
Atar, D
机构
[1] Aker Univ Hosp, Div Cardiol, NO-0514 Oslo, Norway
[2] Frederiksberg Univ Hosp, Dept Cardiol & Endocrinol, Copenhagen, Denmark
关键词
spironolactone; hyperkalemia; adverse effects; heart failure; dyspnea; human; renal function;
D O I
10.1016/j.cardfail.2003.10.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Treatment with spironolactone (SPL) is beneficial in patients with severe congestive heart failure (CHF). In the Randomized Aldactone Evaluation Study SPL was well tolerated, particularly with regard to renal function and serum K+ levels. Our aim was to investigate whether the reported low frequency of adverse effects during SPL treatment in a heart failure study population could be confirmed in an unselected heart failure outpatient cohort and to identify potential predictors of harmful effects. Methods and Results: We investigated 125 consecutive patients with CHIF recruited from our heart failure clinic. Inclusion criteria were LVEF (left ventricular ejection fraction) less than or equal to45% and treatment with SPL. Blood tests were performed bimonthly or more frequently if necessary. Outcomes measures were (1) increases in serum K+ to >5,0, 5.5, 6.0, or 6.5 mmol/L, respectively, and (2) rise in serum creatinine to 120%, 150%, and 200% of baseline, respectively. Mean age was 72.9 years (range 46.5 to 90.6 years); 27% were women. The New York Heart Association class distribution was: I, 6%; II, 44%; III, 46%; and IV, 4%. Mean LVEF was 29 +/- 5%. Other medication included angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in 86% and beta-blockers in 39%. At baseline, serum creatinine levels were 117.6 +/- 6.5 (mean +/- standard deviation; mumol/L, normal <130) and serum K+ was 4.2 +/- 0.3 mmol/L. The mean follow-up period was 11 months, and the cumulative observation period was 73 SPL treatment years. Mean peak serum-creatinine was 167.6 mumol/L +/- 11.9 (45% increase from baseline) and mean peak serum K+ was 5.0 +/- 0.4 mmol/L (21% increase from baseline). Sixty patients were already on SPL when admitted to the CHF clinic. The remainder were initiated on SPL. During the follow-up period 36% of the patients developed hyperkalemia (>5 mmol/L), with 10% having serum K+ >6 mmol/L. An increase in serum creatinine of >20% was seen in 55%, and in 24% an increase of >50% was found. These alterations in serum creatinine and serum K+ were not significantly more frequent in patients treated with angiotensin-converting enzyme inhibitors or beta-blockers or different doses of SPL. Conclusion: SPL adverse effects (impaired renal function, increase in serum K+) are much more prevalent in our elderly CHF patient population than previously reported. The recommendations from our study are that (1) particular caution is mandated in elderly patients with an LVEF <20%, (2) potassium supplementation should be discontinued, (3) changes in body weight should raise concern, and (4) a dose-adjustment of the concomitant conventional diuretic regime should be considered. Care should be given to the frequent monitoring of electrolytes and renal parameters.
引用
收藏
页码:297 / 303
页数:7
相关论文
共 16 条
[1]  
Berry C, 2001, Heart, V85, pE8, DOI 10.1136/heart.85.4.e8
[2]   Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade [J].
Blaustein, DA ;
Babu, K ;
Reddy, A ;
Schwenk, MH ;
Avram, MM .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (06) :662-+
[3]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[4]  
Galatius Soren, 2002, Am Heart J, V144, pE2, DOI 10.1067/mhj.2002.123841
[5]  
GREENBERG B, 2002, J CARDIOVASC PHARM, V38, P59
[6]   Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure -: The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF) [J].
Hjalmarson, Å ;
Goldstein, S ;
Fagerberg, B ;
Wedel, H ;
Waagstein, F ;
Kjekshus, J ;
Wikstrand, J ;
El Allaf, D ;
Vítovec, J ;
Aldershvile, J ;
Halinen, M ;
Dietz, R ;
Neuhaus, KL ;
Jánosi, A ;
Thorgeirsson, G ;
Dunselman, PHJM ;
Gullestad, L ;
Kuch, J ;
Herlitz, J ;
Rickenbacher, P ;
Ball, S ;
Gottlieb, S ;
Deedwania, P .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (10) :1295-1302
[7]   RENAL-FUNCTION IN SEVERE CONGESTIVE-HEART-FAILURE DURING TREATMENT WITH ENALAPRIL (THE COOPERATIVE NORTH SCANDINAVIAN ENALAPRIL SURVIVAL STUDY [CONSENSUS] TRIAL) [J].
LJUNGMAN, S ;
KJEKSHUS, J ;
SWEDBERG, K .
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 70 (04) :479-487
[8]  
MOOSER V, 1987, J CLIN HYPERTENS, V3, P510
[9]  
Pitt B, 1996, AM J CARDIOL, V78, P902
[10]   Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [J].
Pitt, B ;
Remme, W ;
Zannad, F ;
Neaton, J ;
Martinez, F ;
Roniker, B ;
Bittman, R ;
Hurley, S ;
Kleiman, J ;
Gatlin, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14) :1309-1321